1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Infant Bacterial Therapeutics AB Class B

Infant Bacterial Therapeutics AB Class B

82.00
SEK
+1.20
(+1.49%)
-6.08EPS
943.00MMarket Cap
Nov 13Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.03
0.04
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-2.02
-10.06
-7.54
-6.46
-3.76
-4.13
-6.41
-4.01
-5.83
-9.95
-10.16
-4.84
-6.08
Free Cash Flow per Basic Share
-1.13
-13.26
-7.86
-6.22
-4.39
-4.57
-5.2
-4.95
-7.64
-8.19
-8.4
-5.37
-4.76
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.36
22.8
17.19
22.9
49.59
45.46
39.21
35.21
29.55
22.65
12.64
7.82
3.94
Tangible Book Value per Share
1.51
17.86
14.67
20.92
48.36
44.31
38.13
34.2
28.61
21.93
11.98
7.22
3.37
Basic Weighted Avg Shares
3
2
5
6
11
11
11
11
11
12
13
13
13
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
-23,512.35
-15,185.29
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
1
1
1
1
1
1
1
1
1
1
1
Net Income, GAAP
-7
-21
-38
-36
-41
-46
-72
-45
-65
-123
-137
-65
-82
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-23,522.22
-15,191.6
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
5
59
90
154
543
497
428
384
321
295
161
97
45
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
11
75
105
168
557
510
440
395
332
305
170
105
53
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-48.05
-42.33
-26.43
-11.2
-8.68
-15.15
-10.77
-18.01
-38.65
-57.59
-47.29
-87.44

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
680
678
943

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
154
135
112
Cash, Cash Equivalents & STI
144
132
109
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
56
61
67
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.26%
-23.32%
-38.13%
Free Cash Flow
13.53%
8.64%
-36.06%
Net Income, GAAP
21.63%
10.97%
-52.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.06
-3.17
-2.42
-2.51
-10.16
2025
-1.24
-1.42
-0.75
-1.43
-4.84
2026
-1.7
-2.21
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Staffan Strömberg
Full Time Employees
8
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Katarina Bangata 70 Stockholm AB Sweden 116 42
IPO Date
Mar 29, 2016
Website
ibtherapeutics.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Infant Bacterial Therapeutics AB (publ) (IBT) is a clinical-stage pharmaceutical company that develops live biotherapeutic products targeting diseases affecting premature infants and antibiotic-resistant infections; its lead candidate, IBP-9414, a formulation of Lactobacillus reuteri found in breast milk, prevents necrotizing enterocolitis (NEC) and improves feeding tolerance in preterm infants, while its pipeline also includes IBP-1016 for gastroschisis treatment, IBP-1118 to prevent retinopathy of prematurity, and IBP-1122 to eliminate vancomycin-resistant enterococci. Founded in 2011 and headquartered in Stockholm, Sweden, the company pursues global regulatory approvals including FDA, EMA, and others, with Orphan Drug and Rare Pediatric Disease Designations for IBP-9414, and operations spanning Europe and North America through clinical trials and manufacturing partnerships. Recent developments include securing a manufacturing partnership with Recipharm Advanced Bio in November 2025 to initiate Process Performance Qualification (PPQ) for IBP-9414 at their Cuxhaven, Germany facility; receiving FDA Breakthrough Therapy Designation for IBP-9414 in March 2025 for gastrointestinal-related mortality reduction; submitting the Phase 3 Connection Study clinical report to the FDA in May 2025 with ongoing review anticipated to accelerate due to the designation; hiring Nigel Titford as Head of Business Development in Q2 2025 to build sales and distribution channels; completing Phase 3 clinical development; and restructuring operations to prioritize commercialization preparations while advancing analytical method validations and a Biologics License Application.